Investigational drug · Phase 3
lorundrostat
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
1 still active
All registered trials
5
Any phase or sponsor naming "lorundrostat"
First trial start
2023
Mar 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "lorundrostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension
- Obstructive Sleep Apnea
- Chronic Kidney Disease
Approved drugs for the same conditions: High blood pressure (hypertension) · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "lorundrostat" as an intervention, largest first.
- Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionPivotal-lookingCompleted
Mineralys Therapeutics Inc.Industry
NCT06153693 · 1,083 participants · Start Nov 22, 2023 · Primary completion Dec 10, 2024
Drug: Placebo; lorundrostat Dose 1 and 1 more · For: Hypertension
Sites: Alexander City, Alabama; Birmingham, Alabama; Foley, Alabama · 184 sites in all
- Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionPivotal-lookingActive, not recruiting
Mineralys Therapeutics Inc.Industry
NCT05968430 · 1,076 participants · Start Jul 14, 2023 · Primary completion Dec 30, 2025
Drug: lorundrostat; Placebo · For: Hypertension
Sites: Birmingham, Alabama; Foley, Alabama; Chandler, Arizona · 177 sites in all
- A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenPivotal-lookingCompleted
Mineralys Therapeutics Inc.Industry
NCT05769608 · 285 participants · Start Mar 13, 2023 · Primary completion Jan 15, 2025
Drug: Placebo; lorundrostat Dose 1 and 1 more · For: Hypertension
Sites: Birmingham, Alabama; Chandler, Arizona; Mesa, Arizona · 104 sites in all
Mineralys Therapeutics Inc.Industry
NCT06150924 · 60 participants · Start Dec 14, 2023 · Primary completion Feb 27, 2025
Drug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD; Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD · For: Chronic Kidney Disease
Sites: Glendale, Arizona; Phoenix, Arizona; Chula Vista, California · 44 sites in all
Mineralys Therapeutics Inc.Industry
NCT06785454 · 48 participants · Start Feb 28, 2025 · Primary completion Dec 17, 2025
Drug: Lorundrostat; Placebo · For: Obstructive Sleep Apnea; Hypertension
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Little Rock, Arkansas · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging therapeutics in hypertension: Evidence, clinical readiness, and implementation.
Tavethia J, Shivanne Gowda D, Mehta S, et al. · Curr Probl Cardiol 2027
- Effect of fourth-line antihypertensive therapy on clinic systolic blood pressure in resistant hypertension: a systematic review and meta-analysis.
Alam T, Saad M, Ibrahim T, et al. · Blood Press 2026
- Comparative efficacy and safety of lorundrostat and baxdrostat in uncontrolled hypertension: a placebo-anchored indirect treatment comparison using the Bucher method.
Yousif MYE, Mohammed AHA, Mohammed Zaki MAM, et al. · Ann Med Surg (Lond) 2026
- Selective Inhibition of Aldosterone Synthase With Lorundrostat in Uncontrolled Hypertension.
Berezin AE · J Cardiovasc Pharmacol 2026
- Safety and Efficacy of Lorundrostat in Uncontrolled Hypertension: A Systematic Review and Meta-analysis.
Ashraf S, Wani SA, Burhan M, et al. · J Cardiovasc Pharmacol 2026
- The role of aldosterone synthase inhibitors in hypertension: A systematic review and meta-analysis.
Kashyap VK, Asghar A, Mathew C, et al. · JRSM Cardiovasc Dis 2026
Also in development for Hypertension
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- VCT220CX11Phase 35 trials
Vincentage Pharma Co., Ltd · Obesity, Type 2 Diabetes Mellitus (DM), Hypertension
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- ZilebesiranALN-AGT01Phase 34 trials
Alnylam Pharmaceuticals · Hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- DWC202314PPhase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.